Checkpoint Inhibitors Have a Role for'Virtually Every Patient'Checkpoint Inhibitors Have a Role for'Virtually Every Patient '

After an'extraordinary week'of advances in lung cancer, Dr Mark Kris explains why checkpoint inhibitors now play a major role in lung cancer therapy.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Related Links:

Conclusion: Our results indicate that SirT1 regulates apoptosis and radiation sensitization in lung cancer cell lines A549 and H460 via the SirT1/NF- κB/Smac pathway.Cell Physiol Biochem 2018;48:304 –316
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization   Laboratory&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Conclusion: This article provides a brief current overview of literature pertaining to the role of radiation therapy in the management of lung cancer.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Conclusion: The approaches of this review are to highlight the recent management advances and contrast the differences of treatment practice between Western and Asian countries.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Conclusion: In spite of the rapid development of external beam radiation therapy brachytherapy continues to remain an important mode of therapy and is often a default treatment when external beam radiation option is limited.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Palliation may be the goal of care for some patients with intra-thoracic lung cancer. Factors such as the extent of disease, comorbidities, performance status, or symptom burden, may indicate that patients are unsuitable for more aggressive approaches with a curative intent. A palliative treatment plan implies a focus on the effective relief and control of symptoms, while preserving both the quality and quantity of life. Therapeutic measures may include palliative radiotherapy, palliative chemotherapy, or other forms of systemic treatment. In addition, certain interventional procedures may be used to achieve symptom pallia...
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
In Asia, North America and Europe, lung cancer remains one of the top contributors to cancer-related death. Oncology training programs span 4-5 years and palliative care fellowship is around 2 years. However, the multi-disciplinary conference is increasingly viewed as preferable to assist with decision making in most modern centers. Palliative care for lung cancer likewise differs between regions.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
The objectives of the current study were to synthesize and test the effectiveness of a nanotechnology-based strategy utilizing folic acid (FA)-conjugated liposomes that incorporate both celastrol (Cs) and irinotecan (Ir) for targeted breast cancer therapy. Our results revealed the successful preparation of Cs and Ir-loaded folate-targeted liposomes (Lipo/Cs/Ir-FA) with a small particle size (∼190 nm) and polydispersity index (∼0.10). The formulation exhibited higher drug release profiles for both Ir and Cs at pH 5.0 compared to those at physiological pH, favoring cancer cell-targeted release. Furthermore, in vitr...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Publication date: Available online 13 April 2018Source: Respiratory InvestigationAuthor(s): Kohei Otsubo, Isamu Okamoto, Naoki Hamada, Yoichi NakanishiAbstractInterstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non–small cell lung can...
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Publication date: June 2018Source: Pathology - Research and Practice, Volume 214, Issue 6Author(s): Wei Gong, Yi Cao, Yuanyuan Wang, Lei Yang, Wenpeng Su, Fuman Qiu, Soham Datta, Boqi Rao, Jianfeng Xian, Mingzhu Lin, Yingyi Feng, Xin Zhang, Yifeng Zhou, Xingcheng Gao, Jiachun LuAbstractAntisense RNA (AS) is a type of long non-coding RNAs that functions as a post-transcriptional regulatory element on regulating parental coding gene expression via directly binding to complementary mRNA sequences. We aimed to investigate the effect of the AS to FEZF1 gene on non-small cell lung cancer (NSCLC) development. The expression level...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hematology | Lung Cancer